Genedrive Receives CE Mark for Hearing Loss Assay

Nov 21, 2019

|

NEW YORK – Molecular diagnostics company Genedrive announced Monday that its antibiotic-induced hearing loss test, the Genedrive MT-RNR1 ID kit, obtained CE marking.

The test will be used to screen babies for a genetic mutation that can cause lifelong deafness when they are given certain antibiotics. The company said in a statement the RNR1 test is believed to be the first commercial genetic screening test designed for use in an infant emergency care environment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Walking Around

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

For Better Identification

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

There, In the Water

The New York Times reports on how environmental DNA sampling could monitor endangered species.

Cell Studies Look at Endometrial Cancer 'Omics, Antibiotic Discovery Deep Learning, Lymphoma

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.

Featured White Papers

High Throughput SPR Kinetics

A Machine-Learning Framework for Accurate Classification and Quantification of Oncogenic Variants Using the QuantideX NGS DNA Hotspot 21 Kit

BCR-ABL1 Minor Breakpoint (e1a2) Monitoring Using an Analytically Validated Multiplex Assay

Analytical Validation of the QuantideX NGS DNA Hotspot 21 Kit, A Diagnostic NGS System for the Detection of Actionable Mutations in FFPE Tumors

Feb

27

Featured Webinar

Digital PCR Method Development for Accurate Quantification of Copy Number Variations

Since the publication of the “The Digital MIQE Guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments” (dMIQE) in 2013, there has been a large expansion of the applications of dPCR such as single nucleotide variations (SNVs) and copy number variations (CNVs) measurements associated with disease diagnostics.

Mar

18

Featured Webinar

Comparison of Genome-Wide versus Targeted cfDNA Testing for First-Line Prenatal Screening: Real-World Data

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar

31

Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

Menu

Genedrive Receives CE Mark for Hearing Loss Assay

To read the full story....

Breaking News

NanoString Q4 Revenues Up 23 Percent

Adaptive Biotechnologies Q4 Revenues Rise 41 Percent

Natera Q4 Revenues Rise 24 Percent

Researchers Assemble Comprehensive Vaginal Microbiome Gene Catalog

Oral Microbiome Changes Implicated in Gum Inflammation in E-Cigarette Users

BioMérieux Reports 11 Percent Revenue Growth in Q4

The Scan

Walking Around

For Better Identification

There, In the Water

Cell Studies Look at Endometrial Cancer 'Omics, Antibiotic Discovery Deep Learning, Lymphoma

Featured White Papers

Digital PCR Method Development for Accurate Quantification of Copy Number Variations

Comparison of Genome-Wide versus Targeted cfDNA Testing for First-Line Prenatal Screening: Real-World Data

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

What's Popular?

Co-Diagnostics SARS-CoV-2 Assay Garners CE Mark

BioMérieux Reports 11 Percent Revenue Growth in Q4

New T2 Biosystems CEO Plans to Shrink Costs, Sharpen Sales Strategy

Q&A: Hong Kong University's Leo Poon Discusses Diagnostics for SARS-CoV-2

Asuragen Fragile X Diagnostic Test Gets FDA Authorization

Sponsorships